Designing systems that replace coordination with execution

Every pharmacogenomic report demands that someone reconcile a patient's diplotypes against a moving body of evidence — CPIC guidance, FDA label language, DailyMed inserts, DPWG recommendations — and translate it into something a prescriber can act on. Done by hand, that work is a bottleneck: it stalls turnaround, and two qualified reviewers can reach different wording for the same result. As panels widen and reanalysis piles up, the manual burden compounds until interpretation quality drifts.

SignalAI reads your evidence graph and drafts the interpretation — cited, scoped, and never the final word.

SignalAI traverses the same curated evidence graph your reports are built on, mapping each genotype-drug pair to the governing guidance and drafting a recommendation with its sources attached. It is grounded, not generative guesswork — it quotes the evidence it relied on and flags where support is thin rather than inventing a conclusion. Every draft lands in the medical director's queue for review, edit, or rejection; the clinician signs, and the clinician owns the call.

SignalAI does the reconciliation work your analysts do — faster and identically every time:

• Cited drafts from the evidence graph

• Flags thin or conflicting evidence

• Medical-director review on every output

• Consistent wording across reviewers

Reliability comes from grounding and refusal, not fluency. SignalAI is constrained to the evidence graph your lab curates — CPIC, FDA, DailyMed, DPWG — so it cannot cite a source that is not there, and when the evidence for a gene-drug interaction is sparse or contradictory it says so and defers rather than filling the gap with a guess. Because every draft carries the same reasoning and citation structure, the same genotype produces the same interpretation on every report.

SignalAI runs inside the workflow your team already uses — no separate console, no data leaving the platform. Drafts populate the standard report and route straight into the medical director's existing review and sign-out queue, so the human checkpoint is where it has always been. As a HIPAA business associate, SignalPGx keeps all interpretation within the same audited, tenant-isolated boundary as the rest of your reporting.

The gain scales with volume. What took an analyst minutes of database cross-referencing per gene-drug pair becomes a reviewed draft in seconds, so reviewers spend their time confirming judgment rather than assembling it. When a guideline moves, SignalAI re-drafts affected interpretations against the updated evidence, keeping a growing back-catalog of reports consistent without a manual sweep.

Your lab clears reports faster with fewer reviewer-to-reviewer discrepancies, and your medical director keeps full authority over every clinical recommendation — the speed of automation with the accountability clinicians and prescribers require.